Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
5 September 2022 |
Main ID: |
NCT02434081 |
Date of registration:
|
30/04/2015 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
NICOLAS |
Scientific title:
|
A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma |
Date of first enrolment:
|
November 25, 2015 |
Target sample size:
|
94 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT02434081 |
Study type:
|
Interventional |
Study design:
|
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 2
|
|
Countries of recruitment
|
Belgium
|
Germany
|
Netherlands
|
Spain
|
Switzerland
| | | |
Contacts
|
Name:
|
Dirk De Ruysscher, MD PhD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Maastro Clinic, Maastricht, The Netherlands |
|
Name:
|
Solange Peters, MD PhD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
University of Lausanne Hospitals |
| |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
|